Recent advances in the treatment of primary sclerosing cholangitis

References

• Broomé U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610–615.
   PubMed Web of Science ®Google Scholar
• Schramm C, Eaton J, Ringe KI, et al. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology. 2017;66:1675–1688.
   PubMed Web of Science ®Google Scholar
• Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol. 2003;98:1155–1158.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Olsson R, Bergquist A, et al. The natural history of small-duct Primary sclerosing cholangitis. Gastroenterology. 2008;134:975–980.
   PubMed Web of Science ®Google Scholar
• Kirstein MM, Book T, Manns MP, et al. Secondary sclerosing cholangitis in critically ill patients has a poor outcome but lower tumour incidence than primary sclerosing cholangitis. United European Gastroenterol J. 2020;8(6):716–724.
   PubMed Web of Science ®Google Scholar
• Gudnason HO, Björnsson HK, Gardarsdottir M, et al. Secondary sclerosing cholangitis in patients with drug-induced liver injury. Dig Liv Dis. 2015;47:502–507.
   Web of Science ®Google Scholar
• Ahmad J, Rossi S, Rodgers SK, et al. Sclerosing Cholangitis like changes on magnetic resonance cholangiography in patients with drug induced liver injury. Clin Gastroenterol Hepatol. 2018;Epub ahead of print:S1542-3565(18)30692-X. .
   Google Scholar
• Schrumpf E, Abdelnoor M, Fausa, et al. Risk factors in primary sclerosing cholangitis. J Hepatol. 1994;21:1061–1066.
   PubMed Web of Science ®Google Scholar
• Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36:321–327.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Angulo P. Cholangiocarcinoma in young individuals with and without Primary Sclerosing Cholangitis. Am J Gastroenterol. 2007;102:1677–1682.
   PubMed Web of Science ®Google Scholar
• Claessen MMH, Vleggaar FP, Tytgat KMAJ, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158–164.
   PubMed Web of Science ®Google Scholar
• Boonstra K, Weersma RK, van Erpecum, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045–2055.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002;37:1205–1211.
   PubMed Web of Science ®Google Scholar
• Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–526.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Adland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998 January;33(1):99–103. .
   PubMed Web of Science ®Google Scholar
• Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364–1369.
   PubMed Web of Science ®Google Scholar
• Lindkvist B, De Valle M, Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571–577.
   PubMed Web of Science ®Google Scholar
• Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–1188.
   Google Scholar
• Barner-Rasmussen N, Pukkala E, Jussila A, et al. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol. 2020;55:74–81.
   PubMed Web of Science ®Google Scholar
• Gudnason H, Kristinsson JO, Bergmann OM, et al. [Primary sclerosing cholangitis in Iceland 1992-2012]. Frumkomin trefjunargallgangabólga á Íslandi árin 1992–2012. Læknabladid. 2019;105:71–376.
   PubMed Web of Science ®Google Scholar
• Baldursdottir TR, Bergmann OM, Jonasson JG, et al. Epidemiology and the natural history of primary biliary cirrhosis: a nationwide population based study. Eur J Gastroenterol Hepatol. 2012;24:824–830.
   PubMed Web of Science ®Google Scholar
• Toy E, Balasubramanian S, Selmi C, et al. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol. 2011 July 18;11:83.
   PubMed Web of Science ®Google Scholar
• Escorsell A, Pares A, Rodes J, et al. Epidemiology of primary sclerosing cholangitis in Spain. J Hepatol. 1994;21:787–791.
   PubMed Web of Science ®Google Scholar
• Carbone M, Kodra Y, Rocchetti A, et al. Primary sclerosing cholangitis: burden of disease and mortality using data from the national rare diseases registry in Italy. Int J Environ Res Public Health. 2020 April 29;17(9):3095.
   Web of Science ®Google Scholar
• Ang TL, Fock KM, Ng TM, et al. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol. 2002;17:908–913.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Takamori Y, Toda G, et al. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int. 2008 August;28(7):983–989. .
   PubMed Web of Science ®Google Scholar
• Björnsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut. 2002;51:731–735.
   PubMed Web of Science ®Google Scholar
• Kozaka K, Sheedy SP, Eaton JE, et al. Magnetic resonance imaging features of small-duct primary sclerosing cholangitis. Abdom Radiol (NY). 2020;45:2388–2399.
   PubMed Web of Science ®Google Scholar
• Ringe KI, Bergquist A, Lenzen H, et al. Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). Eur J Radiol. 2020 August;129:109101. (55% progressed after 10 years).
   PubMed Web of Science ®Google Scholar
• Gregerio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16 year prospective study. Hepatology. 2001;33:544–553.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Hayee B, Pavlidis P, et al. Contrasting pattern of chronic inflammatory bowel disease in primary and autoimmune Sclerosing Cholangitis. EBioMedicine. 2015;2:1523–1527.
   PubMed Web of Science ®Google Scholar
• Olsson R, Lindgren S, Glaumann H, et al. High prevalence of small-duct Primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and Primary sclerosing cholangitis. Eur J Int Med. 2009;20:190–196.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Chapman RW, Hirschfield G, et al. Overlap syndromes: the international autoimmune hepatitis group position statement on a controversial issue. J Hepatol. 2011;54:374–385.
   PubMed Web of Science ®Google Scholar
• Zenouzi R, Lohse AW. Long-term outcome in PSC/AIH overlap syndrome: does immunosuppression also treat the PSC component? J Hepatol. 2014;61:1189–1191.
   PubMed Web of Science ®Google Scholar
• Mendes FD, Jorgensesen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070–2075.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Chari S, Smyrk T, et al. Immunoglobulin G4 associated cholangitis. Description of an emerging clinical entity based on reviw of the literature. Hepatology. 2007;45:1547–1554.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Chari S, Talwalkar J, et al. Primary Sclerosing Cholangitis associated with elevated immunoglobulinG4: clinical characteristics and response to immunosuppressive therapy. Am J Ther. 2010;18:198–205.
   Web of Science ®Google Scholar
• de Valle MB, Björnsson E, Mueller T, et al. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Dig Liver Dis. 2014;46:903–908.
   PubMedGoogle Scholar
• Ali AH, Bi Y, Machicado JD, et al. The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience. J Gastroenterol. 2020 Aug 8;Online ahead of print. doi:https://doi.org/10.1007/s00535-020-01714-7.
   Google Scholar
• Olsson R, Broomé U, Danielsson A, et al. Spontaneous course of symptoms in primary sclerosing cholangitis: relationships with biochemical and histological features. Hepatogastroenterology. 1999 Jan-Feb;46(25):136–141.
   PubMedGoogle Scholar
• de Valle M, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int. 2012;32:441–448.
   PubMed Web of Science ®Google Scholar
• Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of Primary sclerosing cholangitis. Gastroenterology. 2017 June;152(8):1975–1984.
   Google Scholar
• Trivedi PJ, Crothers H, Mytton J, et al. Effects of Primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel diseases, based on sex, race, and age. Gastroenterology. 2020;159:915–928.
   Google Scholar
• Rudolph G, Gotthardt D, Kloeters-Plachky P, et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol. 2010;53:313–317.
   PubMed Web of Science ®Google Scholar
• Janse M, Lamberts LE, Verdonk RC, et al. IBD is associated with an increase in carcinoma in PSC irrespective of the presence of dominant bile duct stenosis. J Hepatol. 2012;57:473–474.
   PubMedGoogle Scholar
• Ngu JH, Gearry RB, Wright AJ, et al. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011;9:1092–1097.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Tazuma S, Nakazawa T, et al. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. J Hepatobiliary Pancreat Sci. 2017;24:217–225.
   PubMed Web of Science ®Google Scholar
• Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516–1522.
   PubMed Web of Science ®Google Scholar
• Stanich P, Björnsson LK, Gossard AA. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis. 2011;43:309–313.
   PubMedGoogle Scholar
• Lindor KD, Kowdley KV, Luketic VAC, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808–814.
   PubMed Web of Science ®Google Scholar
• Al Mamari S, Djordjevic J, Halliday JS, et al. Improvement of serum alkaline phosphatase to <.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013 February;58(2):329–334.
   PubMed Web of Science ®Google Scholar
• Lindström L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11:841–846.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646–659.
   PubMed Web of Science ®Google Scholar
• Aabakken L, Karlsen TH, Albert J, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL). Clin Guideline Endoscopy. 2018;49:588–608.
   Web of Science ®Google Scholar
• Dave M, Elmunzer BJ, Dwamena BA, et al. Primary sclerosing chol- angitis: meta-analysis of diagnostic performance of MR chol- angiopancreatography. Radiology. 2010;256:387–396.
   PubMed Web of Science ®Google Scholar
• Ravi K, Chari ST, Vege SS, et al. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009;15:1326–1330.
   PubMed Web of Science ®Google Scholar
• Chapman MH, Thorburn D, Hirschfield GM, et al. British society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;66:1–23.
   Google Scholar
• Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–715.
   PubMed Web of Science ®Google Scholar
• Kalaitzakis E, Levy M, Kamisawa T, et al. Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011;9:800–803.
   PubMed Web of Science ®Google Scholar
• Tokala A, Khalili K, Menezes R, et al. Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. AJR Am J Roentgenol. 2014;202:536–543.
   PubMed Web of Science ®Google Scholar
• Deshpande V, Sainani NI, Chung RT, et al. IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol. 2009;22:1287–1295.
   PubMed Web of Science ®Google Scholar
• Kawakami H, Zen Y, Kuwatani M, et al. IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater’s ampulla and the bile duct. J Gastroenterol Hepatol. 2010;25:1648–1655.
   PubMed Web of Science ®Google Scholar
• Oseini AM, Chaiteerakij R, Shire AM, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology. 2011;54:940–948.
   PubMed Web of Science ®Google Scholar
• Moff SL, Kamel IR, Eustace J, et al. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc. 2006;64:219–223.
   PubMed Web of Science ®Google Scholar
• Stiehl A, Rudolph G, Klöters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36:151–156.
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Lindqvist-Ottosson J, Asztely M, et al. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:502–508.
   PubMed Web of Science ®Google Scholar
• Chapman MH, Webster GJ, Bannoo S, et al. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol. 2012;24:1051–1058.
   PubMed Web of Science ®Google Scholar
• Rudolf G, Gotthardt D, Klöters-Plachky P, et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51:149–155.
   PubMedGoogle Scholar
• Rudolf G, Gotthardt D, Kloeters-Plachky P, et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol. 2010;53:313–317.
   PubMed Web of Science ®Google Scholar
• Trikudanathan G, Naveneethan U, Njei B, et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and metaanalysis. Gastrointest Endosc. 2014 May;79(5):783–789. .
   PubMed Web of Science ®Google Scholar
• Naveneethan U, Njei B, Venkatesh PGK, et al. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:943–950.
   PubMed Web of Science ®Google Scholar
• von Seth E, Ouchterlony H, Dobra K, et al. Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis. Liver Int. 2019;39:382–388.
   PubMed Web of Science ®Google Scholar
• Kalaitzakis E, Sturgess R, Kaltsidis H, et al. Diagnostic utility of single-user peroral cholangioscopy in sclerosing cholangitis. Scand J Gastroenterol. 2010;49(10):1–8.
   Google Scholar
• Arnelo U, von Seth E, Bergquist A. Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis. Endoscopy. 2015;47:696–702.
   PubMed Web of Science ®Google Scholar
• Njei B, McCarty TR, Varadarajulu S, et al. Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2016;44:1139–1151.
   PubMed Web of Science ®Google Scholar
• Fung BM, Tabibian JH. Biliary endoscopy in the management of primary sclerosing cholangitis and its complications. Liver Res. 2019;3:106–117.
   PubMedGoogle Scholar
• Hammel P, Couvelard A, O’Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med. 2001;344:418–423.
   PubMed Web of Science ®Google Scholar
• van den Hazel SJ, Wolfhagen EH, van Buuren HR, et al. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy. 2000;32:779–782.
   PubMed Web of Science ®Google Scholar
• Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001;53:308–312.
   PubMed Web of Science ®Google Scholar
• Cazzagon N, Chazouillères Ο, Corpechot C, et al. Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol. 2019;43:387–394.
   PubMed Web of Science ®Google Scholar
• Ponsioen CY, Arnelo U, Bergquist A, et al. No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis. Gastroenterology. 2018;155:752–759.
   PubMed Web of Science ®Google Scholar
• Rupp C, Hippchen T, Bruckner T, et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut. 2019;68:2170–2178.
   Google Scholar
• Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc. 2009;70:80–88.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Jegadeesan R, Nayak S, et al. ERCP-related adverse events in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2015;81:410–419.
   PubMed Web of Science ®Google Scholar
• Bangarulingam SY, Gossard AA, Petersen BT, et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol. 2009;104:855–860.
   PubMed Web of Science ®Google Scholar
• Etzel JP, Eng SC, Ko CW, et al. Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2008;67:643–648.
   PubMed Web of Science ®Google Scholar
• Koskensalo V, Tenca A, Udd M, et al. Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. Ueg J. 2020;8:462–471.
   PubMed Web of Science ®Google Scholar
• Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis. Hepatology. 1992;16:707–714.
   PubMed Web of Science ®Google Scholar
• Lindor KD. Ursodiol for primary sclerosing cholangitis Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997;336:691–695.
   PubMed Web of Science ®Google Scholar
• Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121:900–977.
   PubMed Web of Science ®Google Scholar
• Olsson R, Boberg KM, de Muckadell OS, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled trial. Gastroenterology. 2005;129:1464–1472.
   PubMed Web of Science ®Google Scholar
• Imam MH, Sinakos E, Gossard AA, et al. High dose ursodeoxycholic acid in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:1185–1192.
   PubMed Web of Science ®Google Scholar
• Eaton JE, Silveria MG, Pardi DS, et al. High dose ursodeoxycholic acid is associated with the development of colorectal neoplasia patients with ulcerative colitis and in primary sclerosing cholangitis. Am J Gastroenterol. 2011;106:1638–1645.
   PubMed Web of Science ®Google Scholar
• Saffioti F, Gurusamy KS, Hawkins N, et al. Pharmacological interventions for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2017;3:CD011343
   PubMed Web of Science ®Google Scholar
• Wunch E, Trottier J, Milkiewicz, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 2014;60:931–940.
   PubMed Web of Science ®Google Scholar
• EASL. Clinical practice. Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267.
   PubMed Web of Science ®Google Scholar
• Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–678.
   PubMed Web of Science ®Google Scholar
• Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67:549–558.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Cahzouilleres O, Rousseau A, et al. A placebo controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171–2181.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Hirano K, Isayamo H, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2015;22:766–770.
   PubMed Web of Science ®Google Scholar
• Dejman A, Clark V, Martin P, et al. Fenofibrate improves alkaline phosphatase in primary sclerosing cholangitis. Hepatology. 2013;144(Supplement):51028–51029.
   Google Scholar
• Lemoinne S, Pares A, Reig A, et al. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Clin Res Hepatol Gastroenterol. 2018;42:521–528.
   PubMed Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obethicolic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Vuppalanchi R, Levy C, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol. 2020;73:94–101.
   Google Scholar
• Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves marker of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019;70:788–801.
   PubMed Web of Science ®Google Scholar
• Hirchfield GM, Chazoouilleres O, Drenth JP, et al. Effect of NGM282, an FGF19 analoge, in primary sclerosing cholangitis:a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol. 2019;70:483–493.
   PubMed Web of Science ®Google Scholar
• Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998;27:580–583.
   PubMed Web of Science ®Google Scholar
• Davies YK, Cox KM, Abdullah BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008;47:61–67.
   PubMed Web of Science ®Google Scholar
• Deneau M, Abdou R, Amin M, et al. Clinical outcomes of oral vancomycin therapy with primary sclerosing cholangitis in the Pediatric PSC consortium. Hepatology. 2018. doi:https://doi.org/10.1002/hep.30256.
   Google Scholar
• Tabibian JH, Wedding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2013;37:604–612.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Cederborg A, Åkvist A, et al. Intestinal permeability and bacterial growth of the small bowel in patients with Primary Sclerosing Cholangitis. Scand J Gastroenterol. 2005;40:1090–1094.
   PubMed Web of Science ®Google Scholar
• Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis. Hepatology. 2004;40:1379–1386.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol. 2011;104:83–88.
   Web of Science ®Google Scholar
• Rahimpour S, Nasiri-Toosi M, Khalili H, et al. A triple blinded, randomized, placebo-controlled trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointest Liver Dis. 2016;25:457–464.
   PubMed Web of Science ®Google Scholar
• Ali AH, Damman J, Shah SB, et al. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scand J Gastroenterol. 2020;55:941–950.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Gossard AA, El-Youssef M, et al. Prospective clinical trial of rifaximin therapy for patients primary sclerosing cholangitis. Am J Ther. 2017;24:e56–e63.
   PubMed Web of Science ®Google Scholar
• Shah A, Crawford D, Burger D, et al. Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis. Semin Liver Dis. 2019;39:432–441.
   PubMed Web of Science ®Google Scholar
• Christensen B, Micic D, Gibson PR, et al. Vedolizumab in patients with Primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018;47:753–762.
   PubMed Web of Science ®Google Scholar
• Tse CS, Loftus EV, Raffals LE, et al. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48:190–195.
   PubMed Web of Science ®Google Scholar
• Caron B, Peyrin-Biroulet L, Pariente B, et al. Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicenter cohort study. J Crohns Colitis. 2019;13:1239–1247.
   PubMed Web of Science ®Google Scholar
• Lynch KD, Chapman RW, Keshav S, et al. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2020;18:179–187.
   PubMed Web of Science ®Google Scholar
• Hedin CRH, Sado G, Ndegwa N, et al. Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2020;18:2295–2304.
   PubMed Web of Science ®Google Scholar
• Muir AJ, Levy C, Janssen HLA, et al. Simtuzumab for primary sclerosing cholangitis” phase 2 study results with insights on the natural history of the disease. Hepatology. 2019;69:684–698.
   PubMed Web of Science ®Google Scholar
• EASL. Clinical practice. Guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Fausa O, Haaland T, et al. Faetures of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis according to a scoriong system for the diagnosis of autoimmune hepatitis. Hepatology. 1996;23:1369–1376.
   PubMed Web of Science ®Google Scholar
• Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of modified scoring system. J Hepatol. 2000;33:537–542.
   PubMed Web of Science ®Google Scholar
• van Buuren HRV, van Hoogstraten HJFV, Terkivatan T, et al. High prevalence of autoimmune hepatitis among patients with Primary sclerosing cholangitis. Journal of Hepatology. 2000;33:543–548.
   PubMed Web of Science ®Google Scholar
• Freedman BL, Danford CJ, Patwardhan V, et al. Treatment of overlap syndromes in autoimmune liver disease: a systematic review and meta-analysis. J Clin Med. 2020;9:1449.
   Web of Science ®Google Scholar
• McNair AN, Moloney M, Portman BC, et al. Autoimmune hepatitis overlapping with Primary sclerosing cholangitis in five cases. Am J Gastroenterol. 1998;93:777–784.
   PubMed Web of Science ®Google Scholar
• Luth S, Kanzler S, Frenzel C, et al. Characteristics and long-term prognosis of the Autoimmune hepatitis/Primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol. 2009;43:75–80.
   PubMed Web of Science ®Google Scholar
• Gohlke F, Lohnse A, Dienes HP, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol. 1996;24:699–705.
   PubMed Web of Science ®Google Scholar
• Olsson R, Björnsson E, Bäckman L, et al. Bile duct bacteriology in primary sclerosing cholangitis. A study of explanted livers. J Hepatol. 1998;28:426–432.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Kilander A, Olssson R. Bile duct bacterial isolates in primary sclerosing cholangitis and certain other form of cholestasis. A study of bile cultures from ERCP. Hepatogastroenterology. 2000;47:1504–1508.
   PubMed Web of Science ®Google Scholar
• Chapman MH, Thorburn D, Hirschfield GM, et al. British society of Gastroenterology and UK-PSC guidelines for diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68:1356–1378.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Takada T, Kawarada Y, et al. Antimicrobial therapy for acute cholangitis: tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007;14:59–67.
   PubMedGoogle Scholar
• Kulaksiz H, Rudolph G, Kloeters-Plachky P, et al. Biliary candida infections in primary sclerosing cholangitis. J Hepatol. 2006;45:711–716.
   PubMed Web of Science ®Google Scholar
• Cai SY, Mennone A, Soroka CJ, et al. All-trans retinoic acid improves cholestasis in α- naphthylisothiocyanate-treated rats and Mdr2−/− mice. J Pharmacol Exp Ther. 2014;349:94–98.
   PubMed Web of Science ®Google Scholar
• Assis DN, Abdelghany O, Cai SH, et al. Combination therapy of all-trans retinoic acid with ursodexycholic acid in patients with primary sclerosing cholangitis-a human pilot/. J Clin Gastroenterol. 2017;51:e11–e16.
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Friman S, Broomé U, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol. 2003;38:1176–1183.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Lindström L, Cvancarova M, et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol. 2012;47(8–9):1021–1029. .
   PubMed Web of Science ®Google Scholar
• Fosby B, Melum E, Bjøro K, et al. Liver transplantation in the Nordic countries - an intention to treat and post-transplant analysis from The Nordic liver transplant registry 1982–2013. Scand J Gastroenterol. 2015;50:797–808.
   PubMed Web of Science ®Google Scholar
• Andersen IM, Fosby BKM, Boberg KM, et al. Indications and outcomes in liver transplantation in patients with Primary Sclerosing cholangitis in Norway. Transplant Direct. 2015;1(9):e39. .
   PubMed Web of Science ®Google Scholar
• Lindström L, Jørgensen KK, Boberg KM, et al. Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic multicentre study. Scand J Gastroenterol. 2018;53:297–304.
   PubMed Web of Science ®Google Scholar
• Vannas M, Färkkilä M, Sintonen H, et al. Health-related quality of life before and after liver transplantation in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2020;55:347–353.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Kaido T, Okajima H, et al. Long-term prognosis and recurrence of primary sclerosing cholangitis after liver transplantation: a single-center experience. Transplant Direct. 2017;3:e334.
   PubMed Web of Science ®Google Scholar